SCYNEXIS, Inc. Financing Cash Flow
SCYNEXIS, Inc. (SCYX) reported Financing Cash Flow of $37.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $13.46M.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $24.04M.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$115.00K.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $29.00K, a 6.45% decline year-over-year.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$14.17M.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$139.00K.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$36.72M, a 175.55% decline from fiscal 2022.
- SCYNEXIS, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $48.60M, a 27.59% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $37.50M 10-Q · filed 2026-08-10 | $37.38M derived: sum of 3 quarters · filed 2026-08-10 | $37.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $24.04M 10-Q · filed 2026-05-11 | $23.92M derived: sum of 2 quarters · filed 2026-05-11 | $23.95M derived: sum of 3 quarters · filed 2026-05-11 | $23.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$86.00K derived: sum of 2 quarters · filed 2026-03-04 | -$86.00K derived: sum of 3 quarters · filed 2026-08-10 | -$14.17M 10-K · filed 2026-03-04 |
| 2025-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $29.00K derived: sum of 2 quarters · filed 2026-08-10 | -$14.05M 10-Q · filed 2025-11-05 | -$14.21M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$14.08M 10-Q · filed 2026-08-10 | -$14.24M derived: sum of 3 quarters · filed 2026-08-10 | -$14.21M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$14.08M 10-Q · filed 2026-05-11 | -$14.24M derived: sum of 2 quarters · filed 2026-05-11 | -$14.21M derived: sum of 3 quarters · filed 2026-05-11 | -$14.21M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$124.00K derived: sum of 2 quarters · filed 2026-03-04 | -$124.00K derived: sum of 3 quarters · filed 2026-03-04 | -$139.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $31.00K derived: sum of 2 quarters · filed 2025-11-05 | $16.00K 10-Q · filed 2025-11-05 | -$119.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$15.00K 10-Q · filed 2025-08-13 | -$150.00K derived: sum of 3 quarters · filed 2025-08-13 | -$116.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$15.00K 10-Q · filed 2025-05-15 | -$150.00K derived: sum of 2 quarters · filed 2025-05-15 | -$116.00K derived: sum of 3 quarters · filed 2025-05-15 | -$36.76M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$101.00K derived: sum of 2 quarters · filed 2025-03-12 | -$36.74M derived: sum of 3 quarters · filed 2025-03-12 | -$36.72M 10-K · filed 2025-03-12 |
| 2023-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$36.61M derived: sum of 2 quarters · filed 2024-11-06 | -$36.59M 10-Q · filed 2024-11-06 | -$36.59M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$36.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$36.62M 10-Q · filed 2024-08-08 | -$36.62M derived: sum of 3 quarters · filed 2024-08-08 | -$36.80M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $22.00K 10-Q · filed 2024-05-08 | $22.00K derived: sum of 2 quarters · filed 2024-05-08 | -$161.00K derived: sum of 3 quarters · filed 2024-05-08 | $41.90M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$183.00K derived: sum of 2 quarters · filed 2024-03-28 | $41.88M derived: sum of 3 quarters · filed 2024-03-28 | $48.60M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $41.88M derived: sum of 2 quarters · filed 2023-11-13 | $48.60M 10-Q · filed 2023-11-13 | $79.08M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $42.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $48.78M 10-Q · filed 2023-08-14 | $79.26M derived: sum of 3 quarters · filed 2023-08-14 | $83.80M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $6.72M 10-Q · filed 2023-05-10 | $37.20M derived: sum of 2 quarters · filed 2023-05-10 | $41.73M derived: sum of 3 quarters · filed 2023-05-10 | $73.91M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $30.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $35.01M derived: sum of 2 quarters · filed 2023-03-31 | $67.19M derived: sum of 3 quarters · filed 2023-03-31 | $67.12M 10-K · filed 2023-03-31 |
| 2021-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $36.71M derived: sum of 2 quarters · filed 2022-11-09 | $36.64M 10-Q · filed 2022-11-09 | $116.76M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $32.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $32.11M 10-Q · filed 2022-08-15 | $112.23M derived: sum of 3 quarters · filed 2022-08-15 | $114.00M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$71.00K 10-Q · filed 2022-05-12 | $80.05M derived: sum of 2 quarters · filed 2022-05-12 | $81.82M derived: sum of 3 quarters · filed 2022-05-12 | $93.78M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $80.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $81.89M derived: sum of 2 quarters · filed 2022-03-29 | $93.85M derived: sum of 3 quarters · filed 2022-03-29 | $94.00M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $13.73M derived: sum of 2 quarters · filed 2021-11-10 | $13.88M 10-Q · filed 2021-11-10 | $47.60M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $11.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $12.11M 10-Q · filed 2021-08-16 | $45.83M derived: sum of 3 quarters · filed 2021-08-16 | $49.06M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $152.00K 10-Q · filed 2021-05-17 | $33.87M derived: sum of 2 quarters · filed 2021-05-17 | $37.10M derived: sum of 3 quarters · filed 2021-05-17 | $41.04M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $33.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $36.95M derived: sum of 2 quarters · filed 2021-03-29 | $40.89M derived: sum of 3 quarters · filed 2021-03-29 | $42.30M 10-K · filed 2021-03-29 |
| 2019-09-30 | $3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $7.17M derived: sum of 2 quarters · filed 2020-11-06 | $8.59M 10-Q · filed 2020-11-06 | $9.41M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $5.35M 10-Q · filed 2020-08-10 | $6.17M derived: sum of 3 quarters · filed 2020-08-10 | $6.70M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $1.42M 10-Q · filed 2020-05-11 | $2.24M derived: sum of 2 quarters · filed 2020-05-11 | $2.76M derived: sum of 3 quarters · filed 2020-05-11 | $2.53M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $822.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $1.34M derived: sum of 2 quarters · filed 2020-03-11 | $1.12M derived: sum of 3 quarters · filed 2020-03-11 | $29.42M 10-K · filed 2020-03-11 |
| 2018-09-30 | $521.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $296.00K derived: sum of 2 quarters · filed 2019-11-12 | $28.60M 10-Q · filed 2019-11-12 | $29.92M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $28.08M 10-Q · filed 2019-08-07 | $29.40M derived: sum of 3 quarters · filed 2019-08-07 | $33.00M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $28.31M 10-Q · filed 2019-05-08 | $29.62M derived: sum of 2 quarters · filed 2019-05-08 | $33.22M derived: sum of 3 quarters · filed 2019-05-08 | $35.11M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $4.92M derived: sum of 2 quarters · filed 2019-03-14 | $6.80M derived: sum of 3 quarters · filed 2019-03-14 | $9.99M 10-K · filed 2019-03-14 |
| 2017-09-30 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $5.49M derived: sum of 2 quarters · filed 2018-11-13 | $8.67M 10-Q · filed 2018-11-13 | $13.45M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $5.07M 10-Q · filed 2018-08-09 | $9.85M derived: sum of 3 quarters · filed 2018-08-09 | $24.25M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $3.19M 10-Q · filed 2018-05-08 | $7.96M derived: sum of 2 quarters · filed 2018-05-08 | $22.37M derived: sum of 3 quarters · filed 2018-05-08 | $43.68M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $19.18M derived: sum of 2 quarters · filed 2018-03-13 | $40.49M derived: sum of 3 quarters · filed 2018-03-13 | $40.50M 10-K · filed 2018-03-13 |
| 2016-09-30 | $14.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $35.72M derived: sum of 2 quarters · filed 2017-11-07 | $35.72M 10-Q · filed 2017-11-07 | $35.34M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | $21.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $21.32M 10-Q · filed 2017-08-08 | $20.93M derived: sum of 3 quarters · filed 2017-08-08 | $20.86M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $5.00K 10-Q · filed 2017-05-08 | -$378.00K derived: sum of 2 quarters · filed 2017-05-08 | -$454.00K derived: sum of 3 quarters · filed 2017-05-08 | $37.61M derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$459.00K derived: sum of 2 quarters · filed 2017-03-13 | $37.61M derived: sum of 3 quarters · filed 2017-03-13 | $37.70M 10-K · filed 2017-03-13 |
| 2015-09-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $37.99M derived: sum of 2 quarters · filed 2016-11-07 | $38.08M 10-Q · filed 2016-11-07 | $38.08M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | $38.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $38.16M 10-Q · filed 2016-08-08 | $38.16M derived: sum of 3 quarters · filed 2017-03-13 | |
| 2015-03-31 | $95.00K 10-Q · filed 2016-05-09 | $95.00K derived: sum of 2 quarters · filed 2017-03-13 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $40.80M 10-K · filed 2017-03-13 | ||
| 2014-09-30 | $40.80M 10-Q · filed 2015-11-13 | |||
| 2014-03-31 | -$839.00K 10-Q/A · filed 2014-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |